Seres Therapeutics, Inc.
MCRB
$7.92
-$0.04-0.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 438.00K | 351.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 438.00K | 351.00K | -- | -- | -- |
| Cost of Revenue | 46.24M | 1.81M | 14.63M | 3.53M | 58.73M |
| Gross Profit | -45.80M | -1.46M | -14.63M | -3.53M | -58.73M |
| SG&A Expenses | 7.54M | 9.48M | 10.25M | 11.89M | 12.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.82M | 22.83M | 24.88M | 27.24M | 28.84M |
| Operating Income | -19.38M | -22.48M | -24.88M | -27.24M | -28.84M |
| Income Before Tax | -15.34M | 8.20M | -19.86M | 32.68M | -15.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.34M | 8.20M | -19.86M | 32.68M | -15.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.34M | 8.20M | -19.86M | 32.68M | -15.64M |
| EBIT | -19.38M | -22.48M | -24.88M | -27.24M | -28.84M |
| EBITDA | -18.42M | -21.43M | -23.82M | -26.16M | -27.75M |
| EPS Basic | -1.66 | 0.94 | -2.27 | 3.76 | -1.83 |
| Normalized Basic EPS | -1.12 | -1.36 | -1.43 | -1.40 | 0.15 |
| EPS Diluted | -1.66 | 0.94 | -2.27 | 3.75 | -1.83 |
| Normalized Diluted EPS | -1.12 | -1.36 | -1.43 | -1.40 | 0.15 |
| Average Basic Shares Outstanding | 9.23M | 8.76M | 8.74M | 8.70M | 8.57M |
| Average Diluted Shares Outstanding | 9.23M | 8.77M | 8.74M | 8.71M | 8.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |